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Strontium ranelate: short- and long-term benefits for post-menopausal
women with osteoporosis
C. Roux
Strontium ranelate is a bone-seeking element that has been assessed in post-menopausal osteoporosis in two large double-blind, placebo-
controlled studies. This treatment is able to decrease the risk of vertebral fractures, by 41% over 3yrs, and by 49% within the first year of
treatment. This risk of non-vertebral fractures is decreased by 16% and, in patients at high risk for such a fracture, the risk of hip fracture is
decreased by 36% over 3yrs. Recent 5-yr data from these double-blind, placebo-controlled studies show that the anti-fracture efficacy is
maintained over time. Treatment efficacy with strontium ranelate has been documented across a wide range of patient profiles: age, number
of prevalent vertebral fractures, BMI, as well as family history of osteoporosis and addiction to smoking are not determinants of anti-fracture
efficacy. During these clinical trials, safety was good. Its large spectrum of efficacy allows the use of strontium ranelate in the different
subgroups of patients with post-menopausal osteoporosis.
KEY WORDS: Osteoporosis, Vertebral fracture, Non-vertebral fracture, Strontium ranelate, Anti-fracture efficacy.
Introduction
Osteoporosis is characterized by an increase in bone fragility due
to low bone mass and deterioration of bone quality, occurring
during ageing and after menopause, and leading to an increase in
the risk of fractures. An optimal treatment of osteoporosis would
increase trabecular and cortical bone strength and decrease the
risk of fracture.
The efficacy of strontium ranelate, a drug registered in the
treatment of post-menopausal osteoporosis to reduce the risk of
vertebral and hip fractures, has been assessed in two multicentre,
randomized, double-blind, placebo-controlled trials, scheduled for
5yrs. The Spinal Osteoporosis Therapeutic Intervention (SOTI)
trial studied strontium ranelate’s effect on the risk of vertebral
fractures [1]. The Treatment of Peripheral Osteoporosis
(TROPOS) trial studied the effect of strontium ranelate on the
risk of non-vertebral fractures [2]. These studies were preceded by
a short run-in period called FIRST (Fracture International Run-
in Strontium Ranelate Trial), designed to normalize the calcium/
vitamin D status. The main efficacy criterion (effect of treatment
on vertebral, hip and non-vertebral–non-hip fractures) was
assessed at 3yrs. Five-year data are now available from SOTI
(including 4yrs against placebo) and from TROPOS (5yrs against
placebo). Moreover, because the procedures of acquisition and
central readings were the same, data can be pooled in order to
obtain a large database in which subanalyses can be conducted to
assess appropriately the determinants of efficacy and safety of
strontium ranelate.
SOTI study
The SOTI trial included 1649 post-menopausal women aged
70yrs on average with osteoporosis defined by a lumbar BMD
 0.840g/cm
2 and/or at least one prevalent vertebral fracture (this
last criterion being present in 87.5% of included patients).
The primary efficacy analysis was the incidence of patients with
new vertebral fracture over 3yrs. Strontium ranelate (2g/day)
reduced the risk of new vertebral fracture of 49% at 1 yr, as
compared with placebo [relative risk (RR)¼0.51; 95% CI
0.36,0.74; P 0.001]. The benefit after 3yrs of strontium ranelate
was a reduction of 41% (RR¼0.59; 95% CI 0.48, 0.73; P 0.001)
[1]. The risk of clinical vertebral fracture was reduced to 52% after
1yr of treatment (RR¼0.48; 95% CI 0.29, 0.80; P¼0.003) and to
38% after 3yrs, as compared with the placebo group (RR¼0.62;
95% CI 0.47, 0.83; P 0.001). The number of patients that need
to be treated during 3yrs to prevent one vertebral fracture is nine
(95% CI 6, 14). Over 4yrs, data were available in 1445 patients for
the intent-to-treat analysis (87.6% of randomized patients).
The decrease in vertebral fracture risk over 4yrs was 33%
(RR¼0.67, 95% CI 0.53, 0.81, P<0.001) (Table 1).
Administration of strontium ranelate results in an increase in
levels of serum bone alkaline phosphatase compared with the
placebo group from the third month (8.1%; P 0.001), this
difference persisted at each assessment over 3yrs, while the serum
telopeptide of type I collagen decreased from the third month
( 12.2%; P 0.001) [1]. The changes are moderate, but opposite
and concomitant, and consistent with the potential mechanism of
action of the drug.
TROPOS study
Efficacy of strontium ranelate on non-vertebral fractures has
been evaluated in the TROPOS trial, which included 5091
osteoporotic post-menopausal women aged 74yrs (or 70yrs with
one risk factor of osteoporotic fracture), with a femoral neck
BMD  0.600g/cm
2. The primary efficacy analysis was incidence
over time of patients with at least one osteoporotic peripheral
fracture [2].
The TROPOS study showed a significant reduction in the risk
of non-vertebral fractures by 16% (RR¼0.84; 95% CI 0.702,
0.995; P¼0.04) in the group treated with strontium ranelate
throughout the 3-yr study compared with placebo. The relative
risk was reduced by 19% (P¼0.031) for major fragility fractures
(hip, wrist, pelvis and sacrum, ribs and sternum, clavicle,
humerus) in patients treated with strontium ranelate, compared
with the placebo group [2]. An a posteriori analysis was performed
on a subgroup of patients (n¼1977) at high risk of hip fracture
[t-score   2.4 according to national health and nutrition survey
(NHANES) reference, and age  74yrs]. Over 3yrs of treatment,
strontium ranelate reduced the risk of hip fracture in this
subgroup by 36%, compared with the placebo group
(RR¼0.64; 95% CI 0.412, 0.997; P¼0.046). Efficacy of
strontium ranelate in reducing the risk of vertebral fracture
(secondary efficacy end-point) was confirmed in this study with a
reduction in risk of 39% (RR¼0.61; 95% CI 0.51, 0.73;
P 0.001) over 3yrs in the 3640 patients with available X-rays
(Table 1).
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treat analysis [3]. There was a 15% decrease in the risk of
non-vertebral fractures over 5yrs (RR¼0.85; 95% CI 0.73, 0.99;
P¼0.032). There was a 43% decrease in the risk of hip fracture in
a subset of 1128 patients defined as having a high risk of fractures,
i.e. an age of 74yrs or more, and a BMD t-score   2.4at both
the lumbar spine and the femoral neck; in this subset, the RR
was 0.57 (95% CI 0.33, 0.97; P¼0.036). Although these results
were obtained in a post hoc analysis, it should be pointed out that
no other trial has been conducted so far versus placebo during
5yrs with non-vertebral fracture incidence as an end-point
(Table 1).
Pooled data
The study design, centres, BMD central reading centre and the
X-ray central reading centre were common to both SOTI
and TROPOS studies. Thus, a pre-determined analysis of
pooled data was performed to increase the assessment of the
treatment effect estimate compared with the individual phase III
studies [4].
Age
This was, in particular, an opportunity to assess the efficacy of
strontium ranelate according to age (three subgroups of patients:
aged <70yrs, between 70 and 80yrs (exclusive) and  80yrs),
which is a strong risk factor for fracture. Over the 3-yr follow-up
period, in each subgroup of age, there was a decrease in risk of
incident vertebral fracture in the strontium ranelate group relative
to placebo, and there was no treatment-by-age interaction
(P¼0.652) [4]. The RR reduction was 37% (P¼0.003) in the
younger women (<70yrs), 42% (P<0.001) in women 70–80yrs of
age and 32% (P¼0.013) in the elderly (i.e. women  80yrs of age).
Despite the important contribution of this age group to the
public health burden due to their increase in the risk of fractures,
few studies have focused on fracture prevention in the elderly.
SOTI and TROPOS populations included 1556 (23%) patients
who were  80yrs of age (mean age, 84 3yrs): in the intention-
to-treat (ITT) population, within the first 6 months of treatment,
non-vertebral fractures occurred in 3.7% of the women receiving
placebo and 2.1% of women receiving strontium ranelate: the
risk reduction was 44% (P¼0.066) [5]. Over 3yrs, these propor-
tions were 19.7% of women receiving placebo and 14.2% of
women receiving strontium ranelate; i.e. a risk reduction of 31%
(P¼0.011).
Over 3yrs, hip fractures occurred in 7.4% of the women
receiving placebo and in 5.2% of women receiving strontium
ranelate, and this difference did not reach statistical significance
(P¼0.11). Over 3yrs, major non-vertebral fractures (hip, wrist,
pelvis and sacrum, ribs–sternum, clavicle or humerus) occurred in
17.7% of the women receiving placebo and in 11.5% of those
receiving strontium ranelate: a risk reduction of 37% (P¼0.003).
This efficacy in this specific age group is sustained over 5yrs of
treatment. A pre-planned analysis showed in the intent-to-treat
population that strontium ranelate reduced the risk of vertebral
fracture by 31% (RR¼0.69; 95%CI 0.52, 0.92; P¼0.010), and of
non-vertebral fracture by 26% (RR¼0.74; 95% CI 0.57, 0.95;
P¼0.019), compared with placebo [6].
The SOTI and TROPOS populations also included 353 patients
who were 50–65yrs old. These patients had severe osteoporosis:
baseline lumbar spine t-score was –3.7, and the incidence of
vertebral fractures in the placebo group over 3yrs was 29.6%.
Strontium ranelate decreased the risk of such fractures by 47%
(RR¼0.53; 95% CI 0.33, 0.85; P¼0.006) over 3yrs. This efficacy
in reducing the risk of vertebral fractures was sustained over 4yrs
of treatment with a reduction by 40% (RR¼0.60; 95% CI 0.39,
0.92; P¼0.017) in these early post-menopausal women.
Determinants of fracture
The current perspective is to use the clinical risk factors to
determine the individual risk of fracture and thus, the therapeutic
threshold. Thus, it is relevant to check for any effect of these risk
factors on the anti-fracture efficacy of the chosen drug. This has
been done, using the large database of pooled SOTI and TROPOS
data, assessing BMD, prevalent vertebral fracture, family history
of osteoporosis, baseline BMI and addiction to smoking [4] as
potential determinants of strontium ranelate efficacy.
There was an increase in the incidence of vertebral fractures
according to the number of prevalent vertebral fractures in the
placebo group: 25.2% in patients having only one prevalent
fracture (1110 patients in total, 577 in the placebo group) and
40.3% in patients having two or more prevalent fractures (1365
patients in total, 683 in the placebo group). In each of those
subgroups, there was a decrease in risk of incident vertebral
fracture in the strontium ranelate group relative to placebo. The
risks of experiencing a first vertebral fracture, a second vertebral
fracture, or more than two vertebral fractures were reduced by
48, 45 and 33%, respectively (all of them with P<0.001) with
strontium ranelate. Baseline BMD, family history of osteoporosis,
baseline BMI and addiction to smoking were not determinants of
anti-fracture efficacy [4].
The role of BMD changes in the assessment of strontium
ranelate effects warrants details. During treatment, there is a large
increase in BMD. In SOTI, after 3yrs, the lumbar spine BMD
increased in the patients treated by strontium ranelate compared
with the placebo group (12.7% vs  1.3%, P 0.001). The gain of
femur BMD was also significant (8.3% compared with the
placebo group). In TROPOS, at 3yrs, the BMD in the strontium
ranelate group had increased from baseline by 5.7% at the femoral
neck and 7.1% at the total hip (P 0.001), compared with the
placebo group. The greater attenuation of X-rays by strontium
overestimates the actual BMD. However, and more relevant for
the clinical practice, there is a pragmatic approach looking at the
relationships between the increase in BMD, which in this situation
appears directly linked to compliance, and the decrease in fracture
risk. Thus, it has been observed in SOTI and TROPOS pooled
data that the higher the increase in femoral neck BMD, the lower
the incidence of vertebral fracture [7].
There was no link with the incidence of non-vertebral fractures,
which can be explained by the absence of assessment of falls in this
population, and no link between changes of BMD at the spine and
vertebral fractures, which may be related to the artefactual effect
of lumbar spine OA. Among patients treated with strontium
ranelate, those sustaining new vertebral fractures gain less BMD
(þ4.5 9.1%) than patients without incident vertebral fractures
(þ5.7 7.4%). After controlling for covariates, patients with an
improvement of at least 3% in femoral neck BMD were at a lower
risk of sustaining new vertebral fractures (odds ratio 0.62; 0.42,
0.81) than patients without such improvement. Of the patients
treated with strontium ranelate, 45.7% experienced an absolute
gain of 0.033g/cm
2 in femoral neck BMD after 3-yr treatment,
TABLE 1. Anti-fracture efficacy of strontium ranelate
Fracture Duration (yrs) RR (95% CI)
Vertebral 1 0.51 (0.36, 0.74)
Vertebral 3 0.59 (0.48, 0.73)
Vertebral 4 0.67 (0.53, 0.81)
Clinical vertebral 1 0.48 (0.29, 0.80)
Clinical vertebral 3 0.62 (0.47, 0.83)
Non-vertebral 3 0.84 (0.70, 0.99)
Non-vertebral 5 0.85 (0.73, 0.99)
Hip (post hoc)
a 3 0.64 (0.41, 0.99)
Hip (post hoc)
b 5 0.57 (0.33, 0.97)
aAge >74yrs; t-score hip   2.4 (NHANES).
bAge >74yrs; t-score hip and spine   2.4
(NHANES).
Strontium ranelate and post-menopausal osteoporosis iv21corresponding to the smallest detectable difference in femoral
neck measurement. The risk of a new vertebral fracture in these
patients was reduced by 24% (2–41%) (P¼0.03), compared with
patients without such gain in BMD. These analyses indicate that
the increase in BMD is directly correlated with a better anti-
fracture efficacy. Although the increase in BMD at 1yr was also,
in the same study, an indicator of a decreased fracture risk, a
BMD measurement at 1yr in clinical practice for monitoring of
patients cannot yet be recommended, as there is no evidence that
this may improve patients’ long-term persistence, and, as a
consequence, long-term efficacy of the treatment.
Another question is the persistence of the gain in BMD after
stopping the treatment. In SOTI, treated patients were rando-
mized at the end of the fourth year to placebo or strontium, for a
fifth year. In patients who switched from strontium ranelate
treatment to placebo, there was a significant BMD decrease by 3.2
and 2.5% at lumbar spine and hip, respectively. This decrease in
BMD in the year following the treatment seems to have the same
slope as the one observed for annual increase in BMD during the
first year of treatment. This phenomenon probably reflects the
bone clearance of strontium, and the change in bone remodelling
induced by the end of the treatment.
Safety
In SOTI, tolerability was similar in the strontium ranelate group
and the placebo group. The most common adverse events
consisted of nausea and diarrhoea (6.1% vs 3.6% in the placebo
group). The difference between the two groups disappeared after
the first 3 months. In TROPOS study conducted in 77-yr-old
patients on average, nausea (7.2% vs 4.4%), diarrhoea (6.7% vs
5.0%), headache (3.4 vs 2.4%) and dermatitis and eczema (5.5%
vs 4.1%) were reported more commonly in the strontium ranelate
group, but, again, only during the first 3 months of treatment,
without difference for gastrointestinal disorders between groups
afterwards. Actually, as anti-osteoporotic drugs are administered
to a large number of women, it is important to check for adverse
events in the largest possible population in Phase 3 studies. That
is why the safety of strontium ranelate was evaluated in the
pooled SOTI and TROPOS populations. For adverse events
having an incidence higher than 2%, only nausea and diarrhoea
were different between strontium ranelate and placebo. There
was a small and transient rise in serum creatine phosphokinase
concentrations, which had no clinical consequence during the
studies. A slight increase in the annual incidence of venous
thromboembolism (0.9% vs 0.6%) was observed at 3yrs, and
unchanged since the third year, without any underlying potential
mechanism, as there is no known interaction between strontium
ranelate and parameters of haemostasis.
During post-marketing surveillance, isolated cases of hyper-
sensitivity syndrome or DRESS (Drug Rash with Eosinophilia
and Systemic Symptoms) have been reported. These syndromes
are defined by the presence of skin reactions, fever and systemic
findings, hypereosinophilia, hepatic abnormalities and renal
impairment being the most prominent but inconstant. The clinical
manifestations typically occur within 2–6 weeks after initiating
therapy and in most cases resolved upon discontinuation.
The mechanism has not been elucidated. This syndrome
has been very rarely reported so far (16/570000 patient-years).
However, due to the potential fatal outcome linked to this
syndrome, the treatment should be discontinued immediately and
permanently in case of skin rash, with initiation of an adapted
treatment and medical follow-up.
Quality of life
Few data exist on effects of anti-osteoporotic drugs on quality of
life (QOL). In SOTI, QOL was assessed 6-monthly during 4yrs
using the generic SF-36 questionnaire, and a specific questionnaire
for assessment of QOL in osteoporosis, QUALIOST (Boston,
USA). Qualiost has been validated for internal consistency,
reliability and reproducibility. It is a 23-item module resulting in
a total score and two subscores, one emotional and one physical.
There was no effect of strontium ranelate on SF-36 changes. In
contrast, strontium ranelate prevented the slight deterioration of
QOL assessed by Qualiost observed in the placebo group: mean
baseline total score was 38.5 21 and 40.3 22 in the strontium
ranelate and placebo groups, respectively; the magnitude of the
difference in the change of QOL reached 2 (P<0.05) over 4yrs.
Similar differences were also observed for the two subscores of
Qualiost.
Conclusion
Strontium ranelate reduces both the risk of vertebral
fracture over 4yrs and the risk of non-vertebral fractures over
5yrs. In the context of clinical trials, safety was good. Its large
spectrum of efficacy allows the use of strontium ranelate in the
different subgroups of patients with post-menopausal
osteoporosis.
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Rheumatology key messages
  Strontium ranelate has long-term efficacy in vertebral and non-
vertebral fracture risk.
  Strontium ranelate is effective in the treatment of post-menopausal
osteoporosis.
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